UNVC4ever, Chris Bunka, the CEO of Lexari Bioscien

UNVC4ever, Chris Bunka, the CEO of Lexari Bioscience is intent on up-listing to the NASDAQ. For Chris, it is not just a story like one sees with 90% or more of OTC stocks. Chris states LXRP shares are extremely undervalued, and the world has not yet caught on to the wide spread adoption of DehydraTech technology by big pharma, big tobacco, the cannabis industry, and others. This is a disruptive technology that will change the way drugs are administered. Keep in mind, the major drugs big pharma is interested in combining with LXRP technology are already FDA approved. So what LXRP is offering is a better method of administering the drug, faster acting, and better absorbability. Because DehydraTech by passes the liver, a smaller dose is required to accomplish the same treatment --- this is something the FDA has made a big deal about. Also, because of recent litigation, big tobacco wants to deliver nicotine without the need for smoking, and this is why they are interested. Furthermore, a better way of delivering any kind of COVID-19 treatment should be obvious.

Chris has made it clear he will up-list in way possible, and that includes a R/S. Chris says we are on track for up-listing in the January-February timeframe. LXRP intended to up-list in December (right about now), but COVID-19 hit and that caused great delay. LXRP has already applied for up-listing and that is public information. All the news out recently is expected to increase share value, and I suggest we will see at least the fifty cent range by around the end of January.

I actually suspect we may be higher if one or more big pharma drug steps forward before then with a partnership or joint venture agreement.


Kgem